Histology-Agnostic Drugs: A Paradigm Shift-A Narrative Review.

Area of Science:

• Oncology
• Genomics
• Clinical Trial Design

Background:

• Traditional cancer diagnosis relies on organ-specific pathology.
• Advancements in genomic data reveal cancer's heterogeneity and identify targetable mutations.
• This heterogeneity necessitates new therapeutic strategies beyond a one-size-fits-all approach.

Purpose of the Study:

• To review the challenges associated with histology-agnostic targeted cancer therapies.
• To provide insights into potential solutions and frameworks for these novel approaches.

Main Methods:

• Review of current literature on precision oncology and clinical trial designs.
• Analysis of the emergence and implications of histology-agnostic drug development.
• Exploration of challenges in patient selection and drug efficacy across diverse cancer types.

Main Results:

• Precision medicine, driven by molecular alterations, enables histology-agnostic targeted therapies.
• Novel trial designs, including precision/enrichment strategies, are adapting to new therapeutic agents.
• Approved drugs for histology-agnostic indications exist, but this approach presents multifaceted challenges.

Conclusions:

• Histology-agnostic targeted therapies represent a paradigm shift in cancer treatment.
• Addressing challenges in trial design, drug development, and regulatory frameworks is crucial for success.
• Further research and innovative strategies are needed to optimize the application of these targeted agents across various cancer types.